AMGEN FEBRUARY FEAST CLOSES WITH OBESITY GENE LICENSE; STOCK UP 8.5%
Executive Summary
Amgen is fattening its research prospects þ and steering investor attention away from takeover talk þ by licensing exclusive rights to a gene linked to obesity from the Rockefeller University. The Feb. 28 (Fat Tuesday) announcement of the agreement capped a strong month for Amgen on Wall Street, as the stock climbed 5-3/8 points (8.5%) in February to close at 69. Amgen is placing a large bet on the obesity gene project: the company will pay the university $20 mil. up front, milestone payments "several times that amount" and royalties on sales
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.